Related Experiment Video
Updated: Feb 13, 2026

Monovalent Cation Doping of CH3NH3PbI3 for Efficient Perovskite Solar Cells
Published on: March 19, 2017
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam
Melissa D Barnes1,2, Christopher R Bethel1, Jim Alsop3
1Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Abstract:
Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas-derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with a k2/K of 41,400 M-1 s-1 and a koff of 0.00095 s-1 Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant P. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against P. aeruginosa.
Insights
Relebactam effectively inhibits Pseudomonas-derived cephalosporinase (PDC), a key enzyme in multidrug-resistant Pseudomonas aeruginosa. This combination therapy restores imipenem susceptibility in a significant majority of resistant bacterial isolates.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a major Gram-negative pathogen causing severe infections.
- Pseudomonas-derived cephalosporinase (PDC) is a critical inducible beta-lactamase conferring resistance to cephalosporins in P. aeruginosa.
Purpose of the Study:
- To evaluate the inhibitory activity of relebactam against PDC-3.
- To assess the efficacy of relebactam in restoring imipenem susceptibility in multidrug-resistant P. aeruginosa.
Main Methods:
- Enzymatic assays were performed to determine the inhibition kinetics of relebactam against PDC-3 (k2/K and koff values).
- Susceptibility testing was conducted on clinical isolates of multidrug-resistant P. aeruginosa using imipenem alone and in combination with relebactam or cilastatin.
Main Results:
- Relebactam demonstrated potent inactivation of PDC-3, with kinetic parameters k2/K = 41,400 M-1 s-1 and koff = 0.00095 s-1.
- Relebactam resensitized 62% of multidrug-resistant P. aeruginosa isolates to imipenem.
- Imipenem-cilastatin alone only restored susceptibility in 21% of the isolates.
Conclusions:
- Relebactam is a potent inhibitor of PDC-3, a key beta-lactamase in P. aeruginosa.
- The combination of relebactam with imipenem-cilastatin significantly enhances treatment efficacy against multidrug-resistant P. aeruginosa infections.
More Related Videos
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
X-Inactivation
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Activation and Inactivation of G Proteins
Measurement: Derived Units

